Want to see OSTX full AI Analyst Report?
Top Page
OS Therapies Incorporated
(NYSE MKT:OSTX)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.50
▼(-1.32% Downside)
Action:Reiterated
Date:08/17/26
The score is primarily constrained by weak financial performance (no revenue, deepening losses, persistent cash burn, and negative equity), which elevates funding and balance-sheet risk. Technicals are mixed/neutral, providing limited support. Valuation signals are unfavorable due to losses (negative P/E) and no indicated dividend, while corporate events add some support via new financing but with meaningful covenant and dilution considerations.
Positive Factors
Clinical Funding
The convertible financing supplies resources for clinical and regulatory execution, potentially extending operations and supporting progress toward development milestones. This improves near-term funding capacity, although the secured structure creates offsetting obligations.
Negative Factors
No Commercial Revenue
The absence of commercial revenue means OSTX has not yet demonstrated product-market commercialization or an internal source of funding. Persistent negative gross profit and materially worsening losses leave results dependent on successful development, approvals and future financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Funding
The convertible financing supplies resources for clinical and regulatory execution, potentially extending operations and supporting progress toward development milestones. This improves near-term funding capacity, although the secured structure creates offsetting obligations.
Read all positive factors
OS Therapies Incorporated (OSTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$67.80M
Dividend YieldN/A
Average Volume (3M)735.57K
Price to Earnings (P/E)―
Beta (1Y)0.21
Revenue GrowthN/A
EPS Growth-41.63%
CountryUS
Employees5
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.09
Shares Outstanding46,125,824
10 Day Avg. Volume409,704
30 Day Avg. Volume735,574
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-6.72
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside557.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$2.67M
OS Therapies Incorporated Business Overview & Revenue Model
Company Description
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an...
How the Company Makes Money
null...
OS Therapies Incorporated Financial Statement Overview
Summary
Income Statement
5
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
8
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -374.81K | -363.08K | -2.78K | -4.22K | -805.00 | -1.16M |
| EBITDA | -38.74M | -28.39M | -6.83M | -4.34M | -4.45M | -4.84M |
| Net Income | -39.37M | -28.75M | -8.88M | -7.79M | -6.25M | -7.42M |
Balance Sheet | ||||||
| Total Assets | 6.26B | 6.84M | 5.54M | 798.08K | 509.11K | 325.89K |
| Cash, Cash Equivalents and Short-Term Investments | 205.03M | 269.83K | 5.53M | 38.98K | 171.48K | 80.79K |
| Total Debt | 0.00 | 0.00 | 0.00 | 14.61M | 10.35M | 7.07M |
| Total Liabilities | 20.64M | 12.94M | 4.73M | 24.81M | 18.07M | 11.78M |
| Stockholders Equity | -10.84M | -6.10M | 811.49K | -24.02M | -17.56M | -11.45M |
Cash Flow | ||||||
| Free Cash Flow | -8.44M | -14.24B | -7.28M | -3.01M | -3.79M | -4.41M |
| Operating Cash Flow | -8.44M | -14.24B | -7.28M | -3.01M | -3.79M | -4.40M |
| Investing Cash Flow | 0.00 | -466.42M | 0.00 | 1.15K | 230.88K | 200.47K |
| Financing Cash Flow | 15.94M | 9.44B | 12.78M | 2.87M | 3.65M | 3.05M |
OS Therapies Incorporated Risk Analysis
OS Therapies Incorporated disclosed 66 risk factors in its most recent earnings report. OS Therapies Incorporated reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Our substantial indebtedness and limited cash resources could adversely affect our financial condition and ability to obtain additional financing, and a default under our Secured Notes could result in the loss of substantially all of our assets. Q2, 2026
2.
The terms of our Secured Notes impose significant restrictions on our operations and financing activities, which could limit our financial and operational flexibility. Q2, 2026
3.
An event of default under our Secured Notes could result in acceleration of our obligations and materially adversely affect our financial condition. Q2, 2026
OS Therapies Incorporated Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | $81.82M | -0.76 | -74.90% | ― | ― | 44.73% | |
48 Neutral | $87.85M | -1.09 | -70.14% | ― | ― | 16.04% | |
46 Neutral | $67.80M | -1.35 | -3273.76% | ― | ― | -41.63% | |
46 Neutral | $72.03M | -2.52 | -53.86% | ― | -20.00% | 75.26% | |
44 Neutral | $79.37M | -1.44 | -1266.43% | ― | ― | 49.43% |
* General Sector Average
OSTX
OS Therapies Incorporated
1.44
-0.71
-33.02%
IBIO
Ibio
1.45
0.72
98.09%
XBIT
XBiotech
2.27
-0.94
-29.28%
ACET
Adicet Bio
9.11
-1.45
-13.73%
ELTX
Elicio Therapeutics
3.11
-8.42
-73.03%
ACRV
Acrivon Therapeutics, Inc.
2.05
0.75
57.69%
OS Therapies Incorporated Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
OS Therapies Announces Convertible Note Financing and Warrants
Positive
Aug 12, 2026
On August 10, 2026, OS Therapies Incorporated closed the first tranche of a senior secured convertible note private placement of up to $10 million, issuing $5.405 million in principal notes, common stock, pre‑funded warrants and five‑y...
Business Operations and StrategyPrivate Placements and Financing
OS Therapies Settles Leonite Debt, Issues Bridge Financing
Neutral
Aug 6, 2026
On June 30, 2026, OS Therapies entered into a private placement with Leonite Fund I, LP for a senior secured convertible promissory note of up to $10 million, issuing 275,000 commitment shares and a five-year warrant for up to 1.75 million shares,...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
OS Therapies Ends At-The-Market Equity Sales Program
Negative
Jul 29, 2026
On July 23, 2026, OS Therapies Incorporated notified B. Riley Securities Inc. and JonesTrading Institutional Services LLC that it was terminating its At Market Issuance Sales Agreement, originally signed on August 8, 2025, with the termination eff...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
OS Therapies Secures Convertible Note Financing for Expansion
Positive
Jul 2, 2026
On June 30, 2026, OS Therapies and its subsidiaries entered a private placement with Leonite Fund I for a senior secured convertible note of up to $10 million, with an initial $1.6 million tranche funded on July 2 and follow-on tranches at the inv...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.